Caris Life Sciences Reports Significant Q4 Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy CAI?
Source: NASDAQ.COM
- Significant Revenue Growth: Caris Life Sciences reported fourth-quarter revenue of $292.9 million, a 125% increase from $129.9 million a year earlier, indicating strong market demand and positioning for future business expansion.
- Profitability Shift: The company achieved a net income of $82 million, or $0.28 per share, in Q4, compared to a net loss of $61.9 million, or $1.73 per share, a year prior, marking a significant improvement in profitability and boosting investor confidence.
- 2026 Outlook: Caris expects revenue for 2026 to range between $1.00 billion and $1.02 billion, representing a growth of approximately 23% to 26%, reflecting confidence in future growth, particularly in molecular profiling and pharmaceutical research.
- Operating Expense Projections: The company anticipates operating expenses of $590 million to $595 million in 2026 while expecting to maintain positive free cash flow and adjusted EBITDA, demonstrating strong financial management and sustainable growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAI
Wall Street analysts forecast CAI stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 19.000
Low
30.00
Averages
36.17
High
40.00
Current: 19.000
Low
30.00
Averages
36.17
High
40.00
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Caris Launches AI Insights for Pancreatic Cancer Treatment
- Innovative Tumor Report: Caris Life Sciences has launched the Caris AI Insights™ signature specifically for pancreatic cancer, integrating real-world data from over 550,000 patients to provide clinicians with biologically informed treatment decision support, thereby improving patient outcomes.
- Precision Treatment Selection: The report utilizes Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) to assist physicians in risk categorization and treatment recommendations between FOLFIRINOX and gemcitabine/nab-paclitaxel, enhancing the personalization of therapy.
- FDA-Approved Innovation: Caris received FDA approval in November 2024 for MI Cancer Seek, the first assay to simultaneously utilize WES and WTS, marking the company's leadership in molecular oncology and further advancing precision medicine.
- Future Research Outlook: A publication is expected this year highlighting how Caris AI Insights identifies subsets of patients who may benefit from treatment de-escalation and those likely to benefit from more intensive therapy, showcasing the technology's potential in clinical applications.
See More
US Stocks Decline on Friday, Bank Stocks Plummet
- Market Decline: The S&P 500 index closed down 0.43% on Friday, with the Dow Jones Industrial Average falling 1.05% and the Nasdaq 100 down 0.30%, reflecting heightened investor concerns over the disruptive potential of AI, which has negatively impacted market confidence.
- Bank Stocks Plummet: The collapse of UK private lender Market Financial Solutions Ltd raised fears of rising defaults, leading to significant declines in bank stocks, with Morgan Stanley and Goldman Sachs both down over 7%, indicating instability within the financial sector.
- Economic Data Impact: The US January PPI rose 0.5% month-over-month, exceeding expectations of 0.3%, while the Chicago PMI unexpectedly increased to 57.7, demonstrating economic resilience, although market speculation regarding Fed rate cuts was dampened.
- Rising Oil Prices Pressure: WTI crude oil prices surged over 2% to a 7-month high due to President Trump's pessimistic remarks on Iranian nuclear negotiations, exacerbating geopolitical risks that could further impact airline profits, leading to declines in related stocks.
See More
US Stocks Decline as AI Disrupts Markets
- Market Weakness: The S&P 500 index fell by 0.61%, the Dow Jones Industrial Average dropped by 1.17%, and the Nasdaq 100 index decreased by 0.41%, reflecting investor concerns over the disruptive potential of AI, which has put overall market sentiment under pressure.
- Producer Prices Rise: The US January Producer Price Index (PPI) increased by 0.5% month-over-month and 2.9% year-over-year, exceeding expectations, indicating rising inflationary pressures that could influence the Fed's interest rate decisions and increase market uncertainty.
- Strong Economic Data: Despite the market downturn, the February Chicago PMI unexpectedly rose to 57.7, signaling signs of economic expansion, which may alleviate some investor concerns about a slowdown in economic growth.
- Airline Stocks Under Pressure: With WTI crude oil prices reaching a 6.5-month high, airline stocks are generally declining, with United Airlines down over 8%, reflecting the potential threat of rising fuel costs on airline profitability.
See More
Caris Life Sciences Reports Record Q4 2025 Earnings
- Significant Revenue Growth: Caris Life Sciences achieved total revenues of $293 million in Q4 2025, representing a 125% year-over-year increase, with molecular profiling services revenue reaching $282 million, up 199%, indicating strong market demand and business expansion potential.
- Enhanced Profitability: The company reported a GAAP net income of $82 million, adjusted EBITDA of $106 million, and free cash flow of $39.7 million, marking three consecutive quarters of positive EBITDA and free cash flow, which strengthens its competitive edge and investment flexibility in the industry.
- New Product Launch Plans: Caris plans to launch a new cancer early detection test, Caris Detect, in 2026, which is expected to significantly improve cancer mortality rates and further solidify the company's leadership position in precision medicine.
- Optimistic Future Outlook: The company projects total revenue for 2026 to be in the range of $1.0 billion to $1.02 billion, reflecting a growth of approximately 23% to 26%, with molecular profiling expected to grow by 21% to 22%, showcasing ongoing market growth potential and strategic investment direction.
See More
US Stocks Decline as AI Concerns Weigh on Market Sentiment
- Market Decline: The S&P 500 index fell by 0.90%, the Dow Jones Industrial Average dropped by 1.57%, and the Nasdaq 100 index decreased by 0.71%, reflecting investor concerns over the disruptive potential of AI, which has intensified selling pressure across the market.
- Producer Prices Rise: The US January Producer Price Index (PPI) increased by 0.5% month-over-month and 2.9% year-over-year, surpassing expectations, indicating persistent inflationary pressures that may hinder the Fed's ability to cut interest rates in the near term, negatively impacting stock valuations.
- Geopolitical Risks Intensify: WTI crude oil prices surged over 2% to a 6.5-month high due to disappointing outcomes from US-Iran nuclear talks, raising concerns about potential supply disruptions and adding to investor anxiety in the stock market.
- Mixed Stock Performances: Dell Technologies surged over 10% following a strong sales forecast for its AI servers, while cybersecurity stocks like Zscaler plummeted over 11%, illustrating a divergence in market reactions and reflecting investor caution towards technology stocks.
See More
Caris Life Sciences Reports Strong Q4 Earnings, Beats Expectations
- Earnings Beat: Caris Life Sciences reported Q4 earnings of $0.28 per share, significantly exceeding the consensus loss of $0.03 per share, indicating a notable improvement in profitability.
- Sales Surge: The company achieved a 125% year-over-year increase in sales, reaching $292.89 million, surpassing the market expectation of $208.63 million, demonstrating strong demand and growing market acceptance of its products.
- Future Growth Potential: Caris plans to launch its Caris Detect solution in the first half of 2026, leveraging Whole Genome Sequencing to enhance early cancer detection capabilities, which is expected to represent a significant growth opportunity for the company.
- Positive Stock Reaction: Following the earnings announcement, Caris Life Sciences shares jumped 14.1% to $21.95 in pre-market trading, reflecting market optimism regarding the company's future prospects.
See More
Caris Launches AI Insights for Pancreatic Cancer Treatment
- Innovative Tumor Report: Caris Life Sciences has launched the Caris AI Insights™ signature specifically for pancreatic cancer, integrating real-world data from over 550,000 patients to provide clinicians with biologically informed treatment decision support, thereby improving patient outcomes.
- Precision Treatment Selection: The report utilizes Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) to assist physicians in risk categorization and treatment recommendations between FOLFIRINOX and gemcitabine/nab-paclitaxel, enhancing the personalization of therapy.
- FDA-Approved Innovation: Caris received FDA approval in November 2024 for MI Cancer Seek, the first assay to simultaneously utilize WES and WTS, marking the company's leadership in molecular oncology and further advancing precision medicine.
- Future Research Outlook: A publication is expected this year highlighting how Caris AI Insights identifies subsets of patients who may benefit from treatment de-escalation and those likely to benefit from more intensive therapy, showcasing the technology's potential in clinical applications.
See More
US Stocks Decline on Friday, Bank Stocks Plummet
- Market Decline: The S&P 500 index closed down 0.43% on Friday, with the Dow Jones Industrial Average falling 1.05% and the Nasdaq 100 down 0.30%, reflecting heightened investor concerns over the disruptive potential of AI, which has negatively impacted market confidence.
- Bank Stocks Plummet: The collapse of UK private lender Market Financial Solutions Ltd raised fears of rising defaults, leading to significant declines in bank stocks, with Morgan Stanley and Goldman Sachs both down over 7%, indicating instability within the financial sector.
- Economic Data Impact: The US January PPI rose 0.5% month-over-month, exceeding expectations of 0.3%, while the Chicago PMI unexpectedly increased to 57.7, demonstrating economic resilience, although market speculation regarding Fed rate cuts was dampened.
- Rising Oil Prices Pressure: WTI crude oil prices surged over 2% to a 7-month high due to President Trump's pessimistic remarks on Iranian nuclear negotiations, exacerbating geopolitical risks that could further impact airline profits, leading to declines in related stocks.
See More
US Stocks Decline as AI Disrupts Markets
- Market Weakness: The S&P 500 index fell by 0.61%, the Dow Jones Industrial Average dropped by 1.17%, and the Nasdaq 100 index decreased by 0.41%, reflecting investor concerns over the disruptive potential of AI, which has put overall market sentiment under pressure.
- Producer Prices Rise: The US January Producer Price Index (PPI) increased by 0.5% month-over-month and 2.9% year-over-year, exceeding expectations, indicating rising inflationary pressures that could influence the Fed's interest rate decisions and increase market uncertainty.
- Strong Economic Data: Despite the market downturn, the February Chicago PMI unexpectedly rose to 57.7, signaling signs of economic expansion, which may alleviate some investor concerns about a slowdown in economic growth.
- Airline Stocks Under Pressure: With WTI crude oil prices reaching a 6.5-month high, airline stocks are generally declining, with United Airlines down over 8%, reflecting the potential threat of rising fuel costs on airline profitability.
See More
Caris Life Sciences Reports Record Q4 2025 Earnings
- Significant Revenue Growth: Caris Life Sciences achieved total revenues of $293 million in Q4 2025, representing a 125% year-over-year increase, with molecular profiling services revenue reaching $282 million, up 199%, indicating strong market demand and business expansion potential.
- Enhanced Profitability: The company reported a GAAP net income of $82 million, adjusted EBITDA of $106 million, and free cash flow of $39.7 million, marking three consecutive quarters of positive EBITDA and free cash flow, which strengthens its competitive edge and investment flexibility in the industry.
- New Product Launch Plans: Caris plans to launch a new cancer early detection test, Caris Detect, in 2026, which is expected to significantly improve cancer mortality rates and further solidify the company's leadership position in precision medicine.
- Optimistic Future Outlook: The company projects total revenue for 2026 to be in the range of $1.0 billion to $1.02 billion, reflecting a growth of approximately 23% to 26%, with molecular profiling expected to grow by 21% to 22%, showcasing ongoing market growth potential and strategic investment direction.
See More
US Stocks Decline as AI Concerns Weigh on Market Sentiment
- Market Decline: The S&P 500 index fell by 0.90%, the Dow Jones Industrial Average dropped by 1.57%, and the Nasdaq 100 index decreased by 0.71%, reflecting investor concerns over the disruptive potential of AI, which has intensified selling pressure across the market.
- Producer Prices Rise: The US January Producer Price Index (PPI) increased by 0.5% month-over-month and 2.9% year-over-year, surpassing expectations, indicating persistent inflationary pressures that may hinder the Fed's ability to cut interest rates in the near term, negatively impacting stock valuations.
- Geopolitical Risks Intensify: WTI crude oil prices surged over 2% to a 6.5-month high due to disappointing outcomes from US-Iran nuclear talks, raising concerns about potential supply disruptions and adding to investor anxiety in the stock market.
- Mixed Stock Performances: Dell Technologies surged over 10% following a strong sales forecast for its AI servers, while cybersecurity stocks like Zscaler plummeted over 11%, illustrating a divergence in market reactions and reflecting investor caution towards technology stocks.
See More
Caris Life Sciences Reports Strong Q4 Earnings, Beats Expectations
- Earnings Beat: Caris Life Sciences reported Q4 earnings of $0.28 per share, significantly exceeding the consensus loss of $0.03 per share, indicating a notable improvement in profitability.
- Sales Surge: The company achieved a 125% year-over-year increase in sales, reaching $292.89 million, surpassing the market expectation of $208.63 million, demonstrating strong demand and growing market acceptance of its products.
- Future Growth Potential: Caris plans to launch its Caris Detect solution in the first half of 2026, leveraging Whole Genome Sequencing to enhance early cancer detection capabilities, which is expected to represent a significant growth opportunity for the company.
- Positive Stock Reaction: Following the earnings announcement, Caris Life Sciences shares jumped 14.1% to $21.95 in pre-market trading, reflecting market optimism regarding the company's future prospects.
See More
